Form 4: Soleno Therapeutics Merger: Executive Ownership Changes

Soleno Therapeutics, Inc. reports on executive ownership changes following its merger with Neocrine Biosciences, Inc.

Summary

• This filing details changes in beneficial ownership for Kevin Norrett, Chief Business Officer of Soleno Therapeutics, Inc.
• The transactions occurred on May 18, 2026, in connection with the merger between Soleno Therapeutics, Inc. and Neocrine Biosciences, Inc.
• Kevin Norrett's restricted stock units (RSUs) were cancelled and converted into the right to receive $53.00 in cash per RSU.
• His stock options were also cancelled and converted into a cash payment based on the difference between the merger consideration and the exercise price.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports on a completed transaction (merger) and the resulting cash-out of executive equity, rather than ongoing operational performance or future strategic initiatives.

Positives

• Executive Kevin Norrett received a cash payment of $53.00 per RSU, reflecting the merger consideration.
• Stock options were converted into cash payments, providing a realized gain for the executive.

Negatives

• All previously held RSUs and stock options were cancelled as part of the merger, indicating no continued equity ownership in the merged entity for this executive.
• The filing does not specify the total cash amount received by Kevin Norrett, only the per-unit consideration.

Risks

• The primary risk is the cancellation of all equity holdings (RSUs and stock options) for the reporting person, indicating a complete divestment of direct equity in the surviving entity.
• The merger itself introduces integration risks and potential changes in business strategy that could impact future performance.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on completed transactions related to a merger.

Management Comments

• The merger consideration for vested and unvested RSUs was $53.00 in cash.
• Stock options were cancelled in exchange for a cash payment calculated as the difference between the merger consideration and the per-share exercise price, multiplied by the number of shares covered by the option.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects a common outcome in the biotechnology and pharmaceutical sector where mergers and acquisitions are frequent. Executives often realize significant value from their equity holdings upon a successful acquisition.

Stakeholder Impact

• Shareholders: Holders of common stock and RSUs received cash consideration, realizing value from the merger.
• Executives: Executive Kevin Norrett received cash for his RSUs and stock options, converting equity into liquidity.
• Employees: Other employees holding RSUs or options would have experienced similar conversions to cash.

Next Steps

• The company has completed its merger with Neocrine Biosciences, Inc.
• Executive equity holdings have been converted to cash payments.

Key Dates

Keywords

Form 4, SEC Filing, Soleno Therapeutics, Merger, Executive Ownership, Restricted Stock Units, Stock Options, Kevin Norrett, Neocrine Biosciences, Beneficial Ownership